Abstract
The emergence of the highly transmissible B.1.1.529 Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. In this study, we tested a panel of anti-receptor-binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-7831 (sotrovimab)), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Eli Lilly (LY-CoV555 and LY-CoV016) and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1.529 Omicron isolate. Several mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987 and CT-P59) completely lost neutralizing activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (COV2-2196 and COV2-2130 combination, ~12-fold decrease) or minimally affected (S309). Our results suggest that several, but not all, of the antibodies in clinical use might lose efficacy against the B.1.1.529 Omicron variant.
【초록키워드】 SARS-CoV-2, Efficacy, TMPRSS2, coronavirus, Mutation, antibody, monoclonal antibody, variant, Biotechnology, severe acute respiratory syndrome Coronavirus, omicron, virus, Spike protein, Neutralizing activity, REGN10933, REGN10987, B.1.1.529, respiratory, AstraZeneca, mAbs, Sotrovimab, LY-CoV555, mAb, Combination, Vero, S309, Clinical use, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, anti-receptor-binding domain, parent, Lilly, Regeneron, decrease, Celltrion, TMPRSS2 cells, Vero-hACE2-TMPRSS2 cells, neutralize, tested, affected, reduced, the spike protein, concerning, the antibody, Vir, 【제목키워드】 SARS-CoV-2, neutralization, monoclonal antibody, virus, therapeutic,